WASHINGTON, D.C. (May 17, 2021) – Today Monét Stanford is joining the Association for Accessible Medicines (AAM) as Director in the Policy department. She will collaborate with leadership to identify and respond to key policy issues affecting AAM members. Her role also includes developing and managing research opportunities, writing testimony, public comments, policy papers and other materials, and working with AAM’s communications team on content that advances the strategic goals and mission of the association.
Prior to joining AAM, Monét managed government relations and regulatory affairs for Kaiser Permanente. There, she delivered pharmacy-based expertise during the pre-enactment evaluation of legislation and regulation; authored testimony to federal regulatory agencies, elected representatives and national advocacy organizations; developed a comprehensive regulatory analysis index; provided senior leadership with budget forecast projections in response to passed proposals; and served as the external contact for pharmacy issues. Before that, she served as a Policy Development Specialist at Centene Corporation. That role included developing and revising clinical algorithms to support formulary placement of specialty medicines.
Monét holds a Doctor of Pharmacy from the University of Maryland School of Pharmacy and a Bachelor of Arts in Health Policy and Administration from the University of Maryland Baltimore County. She completed her clinical residency training at Purdue University and formal policy training at the National Association for Chain Drug Stores.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
About AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.